Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603844 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
A Phase 1 study of Solid Tumor, sponsored by Corbus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT06603844 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Corbus Pharmaceuticals. The registered enrollment target is 156 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06603844, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Corbus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, levels of CRB-601 in the blood, and the effect on the participant cancer. This will help researchers understand the right dose of CRB-601 to use for treatment and whether it is an effective treatment to combine with standard of care treatments such as immunotherapy. It will also help the researchers understand whether combining CRB-601 with standard-of-care immunotherapy and immune-priming radiotherapy is a safe and effective approach to treat cancer. Participants in the study will receive CRB-601 via an infusion every two weeks either alone or in combination with immunotherapy. There will be assessments to check on the participants general health status (including blood tests) and adverse effects. Participants will also receive regular CT or MRI scans to evaluate the effect of CRB-601 on their cancer. Participants will continue to visit the clinic every two weeks while they are receiving benefit from treatment. If their cancer progresses, participants will be asked to continue to be followed-up by the researchers to understand long-term outcomes, even if they receive other treatments.
Conditions Studied
Interventions
- DRUG CRB-601 monoclonal antibody
- DRUG Anti-PD-1 monoclonal antibody
Study Locations (20)
California
- UC San Diego Health - Moores Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California San Francisco - San Francisco
Arizona
- SCRI - Arizona Oncology Associates - Tucson
- The University of Arizona Cancer Center - Tucson
Florida
- Advent Health Oncology Hematology - Orlando
- SCRI- Lake Nona DDU - Orlando
Texas
- START - San Antonio - San Antonio
- SCRI- Texas Oncology - Tyler
Virginia
- SCRI - Virginia Cancer Specialists - Fairfax
- SCRI - Oncology and Hematology Associates of Southwest Virginia - Roanoke
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- SCRI - Rocky Mountain Cancer Centers - Denver
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603844
The ClinicalTrials.gov registry entry for NCT06603844 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (29% lower). The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which CRB-601 monoclonal antibody is the first listed.
NCT06603844 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06603844 about?
NCT06603844 is a clinical study titled "First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.". The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expres...
What is the current status of trial NCT06603844?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2024-12-04. Estimated completion is 2026-12-01.
What conditions does trial NCT06603844 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06603844?
The interventions under investigation include: CRB-601 monoclonal antibody (DRUG), Anti-PD-1 monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT06603844?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603844 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.